Swipe Left For English News
上海,
2026年3月22日
值此世界水日，药明生物重申可持续发展承诺，通过负责任的运营方式保护环境，并以高效、循环的用水实践持续降低对环境的影响。
药明生物已连续三年荣登全球环境信息研究中心CDP水安全“A”榜单，彰显其在环境领导力和信息透明度方面的行业标杆地位。这些成就得益于药明生物在可持续水管理方面的承诺与实践，实现公司的水资源管理目标，响应客户的可持续关切，持续加强可持续水管理。
体系化水管理成效显著
药明生物积极响应联合国可持续发展目标（SDG6），公司建立体系化水管理框架，制定明确目标并持续追踪目标达成情况，以2019年为基准年，到2025年计划实现30%用水密度（吨/万元人民币）降低。2025年，公司已高质量完成此目标，这充分印证了我们实现卓越水管理的承诺，以及进一步提升用水效率以及最大限度地减少我们对水资源的影响。
全面推广卓越水管理（WES）计划
为进一步强化水资源管理，药明生物于2024年推出卓越水管理（WES）计划，涵盖水管理、水平衡、水质、安全的饮用水、环境卫生和个人卫生（WASH）等核心议题，持续推动水资源卓越管理。公司全球各基地均能通过WES衡量其可持续水管理绩效水平，寻找改善机会点，以确保业务运营在水资源管理方面达到国际先进水平。2025年，WES已推广至全球10个基地。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
自然资源对人类的生存至关重要，在生物药研究、开发和生产中同样不可或缺。我们致力于通过负责任的运营方式保护环境和追求可持续性，旨在提升环保型水资源管理水平，推动人人享有水和环境卫生。作为绿色生物药解决方案领域的全球领导者，我们始终秉持卓越的ESG理念，并赋能全球合作伙伴，助力其迈向ESG发展新高度。未来，我们将继续携手各方，共同推动整个价值链的可持续发展。
作为联合国全球契约组织（UNGC）成员和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司获得EcoVadis铂金奖章，明晟（MSCI）最高AAA ESG评级、入选道琼斯领先指数；荣登CDP气候变化和供应商参与度两大领域A级榜单；获评晨星Sustainalytics ESG"风险可忽略"最高评级以及"行业最高评级"与"区域最高评级"企业；入选富时社会责任指数系列；入选恒生企业可持续发展基准指数；ISS ESG评级"最佳"奖章认可，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国、新加坡和卡塔尔拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2025年12月底，药明生物帮助客户研发和生产的综合项目高达945个，其中包括74个临床III期项目，25个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
Shanghai,
March 22, 2026
On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact.
WuXi Biologics has been named to the CDP Water Security "A List" for three consecutive years, underscoring an industry-leading performance in environmental stewardship and transparency. This achievement reflects the company's long-standing dedication to sustainable water management, including its diligent efforts to meet water targets, fulfill clients' sustainability expectations, and continually enhance water management practices.
Significant Progress in Systematic Water Management
WuXi Biologics actively supports the United Nations Sustainable Development Goal regarding clean water and sanitation (SDG 6), and has established a comprehensive water management framework with clear targets and ongoing progress tracking. With 2019 as the base year, the company aimed to reduce water consumption intensity by 30% by 2025, and, at the conclusion of 2025, had fully achieved this ambitious goal, demonstrating the company's unflagging commitment to excellence in water stewardship, and the success of its endeavors to improve water efficiency and minimize its environmental footprint.
Roll Out of WES Across Global Operations
To promote and support site-specific water stewardship and management across the company, WuXi Biologics launched a Water Excellence Stewardship (WES) program in 2024 covering such material topics as water governance, water balance, water quality, and safe water/environmental and personal hygiene (WASH). Through WES, each site can assess its own sustainable water management performance, identify improvement opportunities, and ensure alignment with international best practices. By the end of 2025, the WES program had been rolled out at 10 of the company's global sites.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
Natural resources are fundamental to the human well-being, and are indispensable in the the research, development and production of biologics. WuXi Biologics is committed to protecting the environment and pursuing sustainability by operating responsibly, while advancing exemplary water stewardship, and promoting universal access to water and sanitation. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain.
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. In addition to being named to the CDP "A List" for Water Security, the company was named to the CDP "A List" for Climate Change and rated "A" in the CDP Supplier Engagement Assessment; granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Best-in-Class Indices; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng Corporate Sustainability Benchmark Index; and rated as Prime by ISS ESG Corporate Rating.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
